CA2765602C - N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders - Google Patents
N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders Download PDFInfo
- Publication number
- CA2765602C CA2765602C CA2765602A CA2765602A CA2765602C CA 2765602 C CA2765602 C CA 2765602C CA 2765602 A CA2765602 A CA 2765602A CA 2765602 A CA2765602 A CA 2765602A CA 2765602 C CA2765602 C CA 2765602C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- protofibril
- terminal truncated
- alzheimer
- protofibrils
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| US61/221,105 | 2009-06-29 | ||
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2765602A1 CA2765602A1 (en) | 2011-01-06 |
| CA2765602C true CA2765602C (en) | 2021-05-25 |
Family
ID=42832352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2765602A Active CA2765602C (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (https=) |
| EP (2) | EP2448968B1 (https=) |
| JP (3) | JP2012532094A (https=) |
| AU (1) | AU2010267640B2 (https=) |
| CA (1) | CA2765602C (https=) |
| CY (1) | CY1124034T1 (https=) |
| DK (1) | DK2448968T3 (https=) |
| ES (1) | ES2864049T3 (https=) |
| HR (1) | HRP20210611T1 (https=) |
| HU (1) | HUE053949T2 (https=) |
| LT (1) | LT2448968T (https=) |
| PL (1) | PL2448968T3 (https=) |
| PT (1) | PT2448968T (https=) |
| SI (1) | SI2448968T1 (https=) |
| SM (1) | SMT202100237T1 (https=) |
| WO (1) | WO2011001366A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| CA2828433C (en) | 2011-03-16 | 2020-08-04 | Probiodrug Ag | Diagnostic antibody assay |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| WO2017013599A1 (en) | 2015-07-21 | 2017-01-26 | Bioarctic Neuroscience Ab | Method for treatment of traumatic brain injury targeting aggregated peptides |
| BR112019000098A2 (pt) | 2016-07-14 | 2019-04-09 | Bioarctic Ab | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| US20210324056A1 (en) | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| JPWO2021006212A1 (https=) * | 2019-07-08 | 2021-01-14 | ||
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| DK4172199T3 (da) | 2020-06-26 | 2025-08-18 | Bioarctic Ab | Alfa-synuklein-protofibril-bindende antistoffer |
| AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| US20240352109A1 (en) | 2021-08-30 | 2024-10-24 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| AU2022439338A1 (en) | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| PE20252307A1 (es) | 2022-12-22 | 2025-09-22 | Bioarctic Ab | Anticuerpo que se une a abetape3 |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| DE60043165D1 (de) * | 1999-08-04 | 2009-11-26 | Univ Southern California | Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen |
| CA2414772C (en) * | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| WO2004013172A2 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| PT1737891E (pt) * | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| RU2429244C2 (ru) * | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| EP2207568B1 (en) * | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| PT2282758T (pt) * | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
-
2010
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011001366A1 (en) | 2011-01-06 |
| CA2765602A1 (en) | 2011-01-06 |
| AU2010267640A1 (en) | 2012-01-19 |
| JP2017197531A (ja) | 2017-11-02 |
| EP2448968B1 (en) | 2021-01-27 |
| JP6884025B2 (ja) | 2021-06-09 |
| JP2012532094A (ja) | 2012-12-13 |
| HRP20210611T1 (hr) | 2021-05-28 |
| DK2448968T3 (da) | 2021-04-12 |
| JP2019218362A (ja) | 2019-12-26 |
| LT2448968T (lt) | 2021-05-10 |
| ES2864049T3 (es) | 2021-10-13 |
| AU2010267640B2 (en) | 2015-03-05 |
| EP3892633A1 (en) | 2021-10-13 |
| EP2448968A1 (en) | 2012-05-09 |
| US20230295283A1 (en) | 2023-09-21 |
| SI2448968T1 (sl) | 2021-07-30 |
| HUE053949T2 (hu) | 2021-08-30 |
| CY1124034T1 (el) | 2022-05-27 |
| PT2448968T (pt) | 2021-04-30 |
| PL2448968T3 (pl) | 2021-09-13 |
| US20120100129A1 (en) | 2012-04-26 |
| SMT202100237T1 (it) | 2021-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230295283A1 (en) | N-terminal truncated protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's | |
| KR101591206B1 (ko) | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 | |
| US20200215209A1 (en) | Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders | |
| KR101600095B1 (ko) | 모노클로널 항 베타 아밀로이드 항체 | |
| CN101883790B (zh) | 抗淀粉样蛋白β抗体在眼病中的用途 | |
| JP6128535B2 (ja) | 抗体及びその利用 | |
| JP7204235B2 (ja) | 活性型α－シヌクレインに結合する抗体 | |
| CN101325972B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 | |
| JP2022528459A (ja) | 融合構築物及びその使用 | |
| HK40057935A (en) | Antibodies selective for n-terminaltruncated amyloid-p protofibrils/oligomers | |
| HK40007334A (en) | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synucleinrelated disorders | |
| HK1124532B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150501 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250506 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250506 |